<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-057426</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cyclooxygenase 2 and colorectal cancer: therapeutic implications</dc:title>
<dc:description xml:lang="en">There is epidemiological evidence that suggests an inverse association between the consumption of non-steroidal anti-inflammatories (NSAIDs) and the risk of developing certain neoplasms. This association led to the identification of the therapeutic target of these drugs, cyclooxygenase type 2 (COX-2). Later studies have demonstrated that COX-2 is over-expressed in many malignant and pre-malignant lesions of different origins, among which are included colorectal neoplasms. This factor explains the beneficial effect observed with the use of classic NSAIDs and more recently, with selective COX-2 inhibitors (coxibs), in the treatment and/or prevention of several neoplasms</dc:description>
<dc:creator>Castellví-Bel, Sergi</dc:creator>
<dc:creator>Castells, Antoni</dc:creator>
<dc:creator>Balaguer, Francesc</dc:creator>
<dc:creator>Gonzalo, Victòria</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Diversas evidencias epidemiológicas sugieren una asociación inversa entre el consumo de antiinflamatorios no esteroideos (AINE) y el riesgo de desarrollar determinadas neoplasias. Esta asociación condujo a la identificación de la diana terapéutica de estos fármacos, la isoenzima 2 de la ciclooxigenasa (COX-2). Estudios posteriores han demostrado que COX-2 se halla sobreexpresada en múltiples lesiones malignas y premalignas de diversos orígenes, entre las que se incluyen las neoplasias colorrectales. Esta circunstancia explica el efecto beneficioso observado con el uso de AINE clásicos y, más recientemente, con los inhibidores selectivos de la COX-2 (coxibs), en el tratamiento y/o prevención de diversas neoplasias</dc:description>
<dc:source>Gastroenterol Hepatol;30(5): 280-284, may. 2007. tab</dc:source>
<dc:identifier>ibc-057426</dc:identifier>
<dc:title xml:lang="es">Ciclooxigenasa 2 y cáncer colorrectal: implicaciones terapéuticas</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d7694</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d27938^s22079</dc:subject>
<dc:subject>^d30408^s22073</dc:subject>
<dc:subject>^d23595^s22057</dc:subject>
<dc:subject>^d30165^s22079</dc:subject>
<dc:type>article</dc:type>
<dc:date>200705</dc:date>
</metadata>
</record>
</ibecs-document>
